Literature DB >> 21421691

Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system.

Gabrièle Piaton1, Marie-Stéphane Aigrot, Anna Williams, Sarah Moyon, Vanja Tepavcevic, Imane Moutkine, Julien Gras, Katherine S Matho, Alain Schmitt, Heidi Soellner, Andrea B Huber, Philippe Ravassard, Catherine Lubetzki.   

Abstract

Oligodendrocyte precursor cells, which persist in the adult central nervous system, are the main source of central nervous system remyelinating cells. In multiple sclerosis, some demyelinated plaques exhibit an oligodendroglial depopulation, raising the hypothesis of impaired oligodendrocyte precursor cell recruitment. Developmental studies identified semaphorins 3A and 3F as repulsive and attractive guidance cues for oligodendrocyte precursor cells, respectively. We previously reported their increased expression in experimental demyelination and in multiple sclerosis. Here, we show that adult oligodendrocyte precursor cells, like their embryonic counterparts, express class 3 semaphorin receptors, neuropilins and plexins and that neuropilin expression increases after demyelination. Using gain and loss of function experiments in an adult murine demyelination model, we demonstrate that semaphorin 3A impairs oligodendrocyte precursor cell recruitment to the demyelinated area. In contrast, semaphorin 3F overexpression accelerates not only oligodendrocyte precursor cell recruitment, but also remyelination rate. These data open new avenues to understand remyelination failure and promote repair in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421691     DOI: 10.1093/brain/awr022

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  53 in total

1.  Collapsin response mediator proteins (CRMPs) are a new class of microtubule-associated protein (MAP) that selectively interacts with assembled microtubules via a taxol-sensitive binding interaction.

Authors:  Pao-Chun Lin; Perry M Chan; Christine Hall; Ed Manser
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

Review 2.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 3.  Myelin regeneration in multiple sclerosis: targeting endogenous stem cells.

Authors:  Jeffrey K Huang; Stephen P J Fancy; Chao Zhao; David H Rowitch; Charles Ffrench-Constant; Robin J M Franklin
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

4.  FGF22 signaling regulates synapse formation during post-injury remodeling of the spinal cord.

Authors:  Anne Jacobi; Kristina Loy; Anja M Schmalz; Mikael Hellsten; Hisashi Umemori; Martin Kerschensteiner; Florence M Bareyre
Journal:  EMBO J       Date:  2015-03-12       Impact factor: 11.598

Review 5.  Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination.

Authors:  Fabien Binamé; Lucas D Pham-Van; Dominique Bagnard
Journal:  Cell Mol Life Sci       Date:  2021-05-21       Impact factor: 9.261

Review 6.  The oligodendrocyte growth cone and its actin cytoskeleton: A fundamental element for progenitor cell migration and CNS myelination.

Authors:  Elizabeth J Thomason; Miguel Escalante; Donna J Osterhout; Babette Fuss
Journal:  Glia       Date:  2019-11-07       Impact factor: 7.452

Review 7.  Achievements and obstacles of remyelinating therapies in multiple sclerosis.

Authors:  Martin Stangel; Tanja Kuhlmann; Paul M Matthews; Trevor J Kilpatrick
Journal:  Nat Rev Neurol       Date:  2017-11-17       Impact factor: 42.937

8.  PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients.

Authors:  Moaz Qureshi; Mohamed Hatem; Raed Alroughani; Sindhu P Jacob; Rabeah Abbas Al-Temaimi
Journal:  Neuromolecular Med       Date:  2017-05-23       Impact factor: 3.843

Review 9.  Remyelination therapy for multiple sclerosis.

Authors:  Michael B Keough; V Wee Yong
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

10.  Promoting return of function in multiple sclerosis: An integrated approach.

Authors:  Mar Gacias; Patrizia Casaccia
Journal:  Mult Scler Relat Disord       Date:  2013-10-01       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.